An argenx representative will contact you soon, so keep an eye on your inbox.
The term MSE is utilized to describe an MG-ADL score of 0 or 1, indicating that a patient has minimal or no symptoms.1,2
Aiming for MSE as the ultimate goal may allow patients to do more than manage their symptoms. It may give them the ability to get back to some of the daily activities that bring meaning to their lives.1
The image above is a patient portrayal and partial depiction of the MG-ADL scale, which assesses the impact of gMG on daily functions of 8 signs or symptoms that are typically affected in gMG. Each function is scored from 0-3: 0 represents normal function and 3 represents the loss of ability to perform that function. A total score can range from 0-24.
gMG=generalized myasthenia gravis; MG-ADL Myasthenia Gravis Activities of Daily Living; MSE=Minimal Symptom Expression.
—Real patient living with gMG
In 4 clinical studies
*Data was collected from 4 randomized, double-blind clinical trials (one phase 2 trial and three phase 3 trials) across 521 patients 18 years and older. Patients were on at least one standard-of-care therapy with MG-ADL baseline scores ranging from 5 to 11.3-6
†Targeted therapies are treatments that target the underlying pathophysiological pathways of the disease.7
MG-ADL=Myasthenia Gravis Activities of Daily Living; MSE=Minimal Symptom Expression.
Could prescribing targeted therapies alongside traditional therapies help your patients aim for a life with fewer symptoms?
gMG=generalized myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living; MSE=Minimal Symptom Expression.
References: 1. Muppidi S et al. Muscle Nerve. 2022;65(6):630-639. doi:10.1002/mus.27476 2. Uzawa A et al. Acta Neurol Belg. 2023;123(3):979-982. doi:10.1007/s13760-022-02162-1 3. Howard JF Jr et al. Lancet Neurol. 2021;20(7):526-536. doi:10.1016/S1474-4422(21)00159-9 4. Bril V et al. Lancet Neurol. 2023;22(5):383-394. doi:10.1016/S1474-4422(23)00077-7 5. Howard JF Jr et al. JAMA Neurol. 2020;77(5):582-592. doi:10.1001/jamaneurol.2019.5125 6. Howard JF Jr et al. Lancet Neurol. 2017;16(12):976-986. doi:10.1016/S1474-4422(17)30369-1 7. Sánchez-Tejerina et al. J Clin Med. 2022;11(21):6394. doi:10.3390/jcm11216394
An argenx representative will contact you soon, so keep an eye on your inbox.
We’re looking forward to sharing information about innovations in gMG with you. Keep an eye on your inbox for important updates on Raising the Bar in gMG.
gMG=generalized myasthenia gravis.